5-HT1B Agonist Pipeline Insights, 2018 Report - ResearchAndMarkets.com

DUBLIN--()--The "5-HT1B Agonist - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

5-HT1B Agonist - Pipeline Insight, 2018 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-HT1B Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Descriptive coverage of pipeline development activities for 5-HT1B Agonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products

4. Comparative Analysis

5. Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

Companies Mentioned

  • Vernalis
  • Lewis and Clark Pharmaceuticals
  • Heptares Therapeutics
  • Advinus Therapeutics
  • Roche
  • Arcus Biosciences
  • iTeos Therapeutics
  • Faust Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/kwncwj/5ht1b_agonist?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs